New drug trial aims to slow devastating ALS progression
NCT ID NCT07325591
Summary
This study is testing whether an oral drug called tazbentetol can slow the progression of ALS and improve patients' daily function and quality of life. It will involve about 430 adults with ALS, who will receive either the drug or a placebo for 36 weeks. The main goal is to see if the drug helps people maintain their physical abilities longer compared to a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.